DNMT3B and metastatic malignant neoplasm: It was found that DNMT3B mediated epigenetic reprogramming in metastases, innovatively linking the metastatic microenvironment to epigenetic alterations occurring in metastases, which suggested that DNMT3B could be an underlying target for the treatment of metastatic cancer (So et al., 2020).